ASHA 044
Alternative Names: ASHA-044Latest Information Update: 27 Oct 2023
At a glance
- Originator Asha Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Beta catenin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Liver cancer; Malignant melanoma
Most Recent Events
- 26 Sep 2023 Preclinical trials in Colorectal cancer in USA (unspecified route) (Asha Therapeutics pipeline, September 2023)
- 26 Sep 2023 Preclinical trials in Liver cancer in USA (unspecified route) (Asha Therapeutics pipeline, September 2023)
- 26 Sep 2023 Preclinical trials in Malignant melanoma in USA (unspecified route) (Asha Therapeutics pipeline, September 2023)